Outcomes studies of drug induced ulcer complications: Do we need them and how should they be done?

BMJ

Volumn 321, Issue 7256, 2000, Pages 291-293

  Hawkey, C J ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROTON PUMP INHIBITOR; ROFECOXIB;

CARDIOVASCULAR DISEASE; GASTROINTESTINAL ENDOSCOPY; HUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; SHORT SURVEY; STOMACH ULCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; EPIDEMIOLOGIC METHODS; GASTRIC MUCOSA; GREAT BRITAIN; HUMANS; STOMACH ULCER; TREATMENT OUTCOME;

EID: 0034729958     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.321.7256.291     Document Type: Article

References (28)

1. Hawkey CJ. Non-steroidal anti-inflammatory drugs and ulcers: facts and figures multiply, but do they add up? BMJ 1990; 300: 278–284.
2. Tramer MR, Moore RA, Reynolds DJ, McQuay HJ. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 2000; 85: 169–182.
3. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 1988; 2: 1277–1280.
4. Graham DY, White RH, Moreland LW, Schubert TT, Katz RR, Jaszewski R, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 1993; 119: 257–262.
5. Elliott SL, Yeomans ND, Buchanan RRC, Smallwood RA. Efficacy of 12 months' misoprostol as prophylaxis against NSAID-induced gastric ulcers: a placebo controlled trial. Scand J Gastroenterol 1994; 23: 171–176.
6. Koch M, Capurso L, Dezi A, Ferrario F, Scarpignato C. Prevention of NSAID-induced gastroduodenal mucosal injury: meta-analysis of clinical trials with misoprostol and H2-receptor antagonists. Dig Dis 1995; 1: 62–74.
7. Raskin JB, White RH, Jaszewski R, Korsten MA, Schubert TT, Fort JG. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a protective, double-blind, multicentre study. Am J Gastroenterol 1996; 91: 223–227.
8. Yeomans ND, Tulassay Z, Juhász L, Rácz I, Howard JM, van Rensburg CJ, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998; 338: 719–726.
9. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, et al. Omeprazole compared with misoprostol for ulcers associated with non-steroidal anti-inflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998; 338: 727–734.
10. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory drugs. Ann Intern Med 1995; 123: 241–249.
11. Chan FKL, Sung JJY, Suen R, Lee YT, Leung WK, Leung VKS, et al. Eradication of H pylori versus maintenance acid suppression to prevent recurrent ulcer haemorrhage in high-risk NSAID users. A prospective randomised study. Gastroenterology 1998; 114: A87.
12. Luong C, Miller A, Barnett J, Chow J, Ramesha C, Browner MF. Flexibility of the NSAID binding site in the structure of cyclooxygenase-2. Nature Struct Biol 1996; 3: 927–933.
13. Hawkey CJ. COX-2 inhibitors. Lancet 1999; 353: 307–314.
14. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Non-steroidal anti-inflammatory drug selectivities for cyclooxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999; 96: 7563–7568.
15. Scott LJ, Lamb HM. Rofecoxib. Drugs 1999; 58: 499–505.
16. Boyce EG, Breen GA. Celecoxib: a COX-2 inhibitor for the treatment of osteoarthritis and rheumatoid arthritis. Hospital Formulary 1999; 34: 405–417.
17. Wight NJ, Garlick N, Calder N, Dallob A, Gottesdiener K, Hawkey CJ. Evidence that the COX-2 specific inhibitor rofecoxib at 50 mg spares gastric mucosal prostaglandin synthesis in humans. Gut 1999; 45(suppl V):30–33.
18. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwlker S, Schwartz, et al. Preliminary study of the safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998; 41: 1591–1602.
19. Lanza FL, Rack MF, Simon TJ, Quan H, Bolognese JA, Hoover ME, et al. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther 1999; 13: 761–767.
20. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase-2 specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999; 117: 776–783.
21. Emery P, Zeiler H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999; 354: 2106–2111.
22. Hawkey CJ, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E, et al for the Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Comparison of the effect of rofecoxib (a cyclooxygenase-2 inhibitor), ibuprofen and placebo on the gastroduodenal mucosa of patients with osteoarthritis. Arthritis Rheum 2000; 43: 370–377.
23. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao P-L, Quan H. H pylori induced incidence of upper gastrointestinal perforations, symptomatic ulcers and bleeding (PUBS). Rofecoxib compared to NSAIDs. JAMA 1999; 282: 1929–1933.
24. Goldstein JL, Agrawal NM, Silverstein F, Kaiser J, Burr AM, Verburg KM, et al. Celecoxib is associated with a significantly lower incidence of clinically significant upper gastrointestinal (UGI) events in osteoarthritis (OS) and rheumatoid arthritis (RA) patients as compared to NSAIDs. Gastroenterology 1999; 116: A17.
25. Hawkey CJ, Kahan A, Steinbruck K, Alegre C, Naumelou E, Begaud B, et al the International MELISSA Study Group. Gastrointestinal tolerability of the COX-2 inhibitor, meloxicam, in osteoarthritis patients: the meloxicam large scale international study safety assessment (MELISSA). Br J Rheumatol 1998; 37: 937–945.
26. ISIS-1 (First International Study of Infarct Survival) Collaborative Groups. Randomized trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction. Lancet 1986; 2: 57–66.
27. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1994; 343: 115–122.
28. Hawkey CJ, Cullen DJE, Greenwood DC, Wilson JV, Logan RFA. Prescribing of non-steroidal anti-inflammatroy drugs in general practice: determinants and consequences. Aliment Pharmacol Ther 1997; 11: 293–298.